Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mint-Rosuvastatin · DIN 02397811 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-08-29 Health Canada: Marketed since 2026-06-15 · brand MINT-ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 20 MG · company Mint pharmaceuticals inc · schedule Prescription

DIN 02397811: Mint-Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600047; group id 308; item number 0676; lccId None; manufacturer id MIN Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1692; ministry $0.1692 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397811 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88273

Interchangeable products

Ach-Rosuvastatin · DIN 02438933 · $0.1692 Apo-Rosuvastatin · DIN 02337991 · $0.1692 Auro-Rosuvastatin · DIN 02442590 · $0.1692 Co Rosuvastatin · DIN 02339781 · $0.1692 Crestor · DIN 02247163 · $0.1692 Jamp Rosuvastatin Calcium · DIN 02498359 · $0.1692 Jamp-Rosuvastatin · DIN 02391279 · $0.1692 M-Rosuvastatin · DIN 02496550 · $0.1692 Mar-Rosuvastatin · DIN 02413086 · $0.1692 Med-Rosuvastatin · DIN 02399180 · $0.1692 NRA-Rosuvastatin · DIN 02477505 · $0.1692 NRA-Rosuvastatin Tablets · DIN 02536625 · $0.1692 PMS-Rosuvastatin · DIN 02378558 · $0.1692 PRZ-Rosuvastatin · DIN 02505592 · $0.1692 Rosuvastatin · DIN 02405644 · $0.1692 Rosuvastatin · DIN 02411644 · $0.1692 Sandoz Rosuvastatin · DIN 02338742 · $0.1692 Taro-Rosuvastatin · DIN 02382660 · $0.1692 Teva-Rosuvastatin · DIN 02354624 · $0.1692

Shortage status: not checked (no credentials)